| Literature DB >> 26484014 |
Hye Min Choi1, Sun Chul Kim2, Myung-Gyu Kim2, Sang-Kyung Jo2, Won Yong Cho2, Hyoung Kyu Kim2.
Abstract
BACKGROUND: It was previously known that anuric acute kidney injury (AKI) is uncommon and its occurrence suggests complete ureteral obstruction, shock, or a major vascular event. As the epidemiology of AKI has significantly changed over the past decade, it is possible that the incidence, etiology, or clinical characteristics of anuric AKI have also changed.Entities:
Keywords: Acute kidney injury; Anuria; Criteria; Epidemiology; Oliguria
Year: 2014 PMID: 26484014 PMCID: PMC4570603 DOI: 10.1016/j.krcp.2014.11.002
Source DB: PubMed Journal: Kidney Res Clin Pract ISSN: 2211-9132
Figure 1Study cohort.
AKI, Acute kidney injury; CKD, chronic kidney disease; RRT, renal replacement therapy.
Causes of acute kidney injury requiring renal replacement therapy
| Anuric AKI( | Nonanuric AKI ( | ||
|---|---|---|---|
| Oliguric( | Nonoliguric( | ||
| Hospital-acquired AKI | 26 (60.5) | 29 (50.9) | 33 (32.0) |
| Cause of AKI | |||
| Sepsis | 18 (41.8) | 29 (50.9) | 49 (47.6) |
| Postoperative AKI | 13 (30.2) | 7 (12.3) | 2 (1.9) |
| Cardiorenal syndrome | 5 (11.6) | 5 (8.8) | 9 (8.7) |
| Hepatorenal syndrome | 2 (4.7) | 2 (3.5) | 1 (1.0) |
| Nephrotoxic drugs | 1 (2.3) | 2 (3.5) | 10 (9.7) |
| Postrenal | – | – | 11 (10.7) |
| Hypovolemia | – | 3 (5.3) | 10 (9.7) |
| Vasculitis, glomerulopathy | 1 (2.3) | 1 (1.8) | 4 (3.9) |
| Rhabdomyolysis | 1 (2.3) | 4 (7.0) | – |
| Other | 2 (4.7) | 4 (7.0) | 7 (6.8) |
Data are presented as n (%).
AKI, acute kidney injury.
Urinary tract obstruction from stone, malignancy etc.
Baseline characteristics of patients with acute kidney injury who required renal replacement therapy
| Anuric AKI ( | Oliguric AKI ( | Nonoliguric AKI ( | ||||
|---|---|---|---|---|---|---|
| Age (y) | 59.4±19.9 | 64.0±14.6 | 66.1±14.6 | 0.072 | 0.071 | 0.058 |
| Male sex | 62.8 | 49.1 | 63.1 | 0.195 | 0.256 | 0.605 |
| Baseline Cr (mg/dL) | 1.01±0.24 | 1.03±0.34 | 1.12±0.36 | 0.163 | 0.057 | 0.269 |
| Baseline eGFR (mL/min/1.73 m2) | 75.1±21.0 | 73.9±23.6 | 70.4±24.6 | 0.514 | 0.256 | 0.433 |
| Comorbidities | ||||||
| CKD | 26.3 | 31.4 | 48.0 | 0.028 | 0.011 | 0.046 |
| CKD(3) | 21.1 | 26.9 | 42.9 | 0.024 | 0.009 | 0.056 |
| Diabetes | 22.0 | 36.8 | 42.6 | 0.069 | 0.105 | 0.030 |
| Liver cirrhosis | 5.0 | 17.0 | 6.0 | 0.047 | 0.205 | 0.532 |
| Malignancy | 26.2 | 21.4 | 18.8 | 0.614 | 0.488 | 0.396 |
Data are presented as mean±SD values or %.
ANOVA, analysis of variance; AKI, acute kidney injury; CKD, chronic kidney disease; Cr, creatinine; eGFR, estimated glomerular filtration rate; RRT, renal replacement therapy; SD, standard deviation.
P, obtained by one-way ANOVA or χ2 test among three groups.
P1, obtained by Student t test or Fisher’s exact test between two groups (anuric+oliguric vs. nonoliguric).
P2, between two groups (anuric vs. oliguric+nonoliguric).
Clinical characteristics and outcomes of patients with acute kidney injury who required renal replacement therapy
| Anuric AKI ( | Oliguric AKI ( | Nonoliguric AKI ( | ||||
|---|---|---|---|---|---|---|
| At start of dialysis | ||||||
| Serum Cr (mg/dL) | 3.8±2.2 | 4.2±2.8 | 4.9±2.9 | 0.071 | 0.050 | 0.091 |
| ICU treatment | 81.4 | 86.0 | 70.9 | 0.071 | 0.030 | 0.543 |
| Vasoactive drugs | 53.5 | 49.1 | 42.7 | 0.453 | 0.262 | 0.390 |
| Mechanical ventilator | 46.5 | 50.9 | 38.9 | 0.215 | 0.095 | 0.492 |
| RRT mode (CRRT) | 72.1 | 64.9 | 46.6 | 0.007 | 0.003 | 0.036 |
| MODS | 39.5 | 29.8 | 13.6 | 0.002 | 0.001 | 0.008 |
| Peak serum Cr (mg/dL) | 5.3±2.7 | 5.0±2.8 | 5.4±2.9 | 0.701 | 0.465 | 0.980 |
| In-hospital deaths | 60.5 | 52.6 | 34.0 | 0.005 | 0.002 | 0.025 |
| Survivors ( | ||||||
| RRT dependence for at least 3 mo | 41.2 | 22.2 | 10.3 | 0.010 | 0.012 | 0.013 |
Data are presented as mean±SD values or %.
ANOVA, analysis of variance; AKI, acute kidney injury; CRRT, continuous renal replacement therapy; Cr, creatinine; ICU, intensive care unit; MODS, multiple organ dysfunction syndrome; RRT, renal replacement therapy; SD, standard deviation.
P obtained by one-way ANOVA or χ2 test among three groups.
P1 obtained by Student t test or Fisher’s exact test between two groups (anuric+oliguric vs. nonoliguric).
P2 between two groups (anuric vs. oliguric+nonoliguric).
Figure 2Overall survival curves according to the volume of urine at the time of initiation of renal replacement therapy.
Univariate and multivariate analyses for predicting 90-day mortality rates
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| Crude HR (95% CI) | Adjusted HR (95% CI) | |||
| Age (y) | 1.00 (0.99–1.02) | 0.513 | ||
| Male sex | 1.31 (0.86–2.01) | 0.214 | ||
| Cause of AKI (septic) | 2.64 (1.71–4.07) | <0.001 | 1.69 (1.04–2.76) | 0.036 |
| Cause of AKI (postoperative) | 0.41 (0.16–1.01) | 0.052 | ||
| Hospital-acquired AKI | 1.77 (1.17–2.67) | 0.007 | ||
| Baseline Cr (mg/dL) | 0.56 (0.27–1.16) | 0.119 | ||
| Baseline eGFR (mL/min/1.73 m2) | 1.01 (1.00–1.02) | 0.128 | ||
| Comorbidities | ||||
| CKD | 0.52 (0.28–0.96) | 0.048 | ||
| Diabetes | 0.77 (0.49–1.21) | 0.263 | ||
| Liver cirrhosis | 1.99 (1.05–3.77) | 0.033 | ||
| Malignancy | 1.09 (0.66–1.79) | 0.745 | ||
| At the time of dialysis | ||||
| Vasoactive drug | 4.93 (3.10–7.86) | <0.001 | ||
| Mechanical ventilation | 7.36 (4.48–12.08) | <0.001 | 5.15 (2.89–9.18) | <0.001 |
| RRT Mode (CRRT) | 4.10 (2.46–6.81) | <0.001 | ||
| Serum Cr (mg/dL) | 0.67 (0.59–0.77) | <0.001 | 0.77 (0.67–0.90) | 0.002 |
| Anuric AKI | 1.90 (1.21–3.00) | 0.006 | 1.86 (1.11–3.11) | 0.019 |
AKI, acute kidney injury; CI, confidence interval of the estimated HR; CKD, chronic kidney disease; CRRT, continuous renal replacement therapy; Cr, creatinine; eGFR, estimated glomerular filtration rate; HR, hazard ratio estimated from the Cox proportional hazard model; RRT, renal replacement therapy.
Variables with P<0.05 in the univariate analyses were assessed as independent predictors using the multivariate model by the forward conditional method.
Clinical characteristics according to the presence of chronic kidney disease
| Variable | Without prior CKD | With prior CKD | |
|---|---|---|---|
| Age (y) | 61.1±17.1 | 69.7±12.1 | <0.001 |
| Male sex | 64.4 | 49.3 | 0.051 |
| Baseline Cr (mg/dL) | 0.90±0.17 | 1.45±0.34 | <0.001 |
| Baseline eGFR (mL/min/1.73 m2) | 84.6±17.6 | 47.8±14.7 | <0.001 |
| At the time of RRT initiation | |||
| Vasoactive drugs | 51.5 | 38.0 | 0.077 |
| Mechanical ventilation | 47.7 | 36.6 | 0.140 |
| Modality of RRT (CRRT) | 64.4 | 43.7 | 0.005 |
| MODS | 28.8 | 14.1 | 0.024 |
| Serum Cr (mg/dL) | 5.57±3.0 | 3.14±1.57 | 0.003 |
| Anuric AKI | 24.6 | 13.9 | 0.056 |
| Anuria+Oliguric AKI | 55.3 | 34.7 | 0.007 |
| Peak serum Cr (mg/dL) | 4.97±2.66 | 5.74±2.88 | 0.070 |
| Outcome | |||
| In-hospital mortality | 50.8 | 33.8 | 0.026 |
| RRT dependence for at least 3 mo | 16.9 | 19.1 | 0.806 |
Data are presented as mean±SD values or %.
AKI, acute kidney injury; CKD, chronic kidney disease; Cr, creatinine; CRRT, continuous renal replacement therapy; eGFR, estimated glomerular filtration rate; MODS, multiple organ dysfunction syndrome; RRT, renal replacement therapy; SD, standard deviation.